Biodexa Pharmaceuticals (BDRX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including GIST, FAP, NMIBC, and T1D.

• Pipeline includes eRapa (licensed from Emtora Biosciences), MTX240 (licensed from Otsuka), and tolimidone, each targeting specific disease mechanisms and patient populations.

• eRapa has received FDA fast track designation and significant grant funding for Phase 3 trials in FAP.

• MTX240 is designed to address resistance in GIST patients, with plans to initiate Phase 1b/2a studies.

• Tolimidone is in Phase 2a for T1D, focusing on insulin signaling and beta cell survival.

Financial performance and metrics

• As of June 30, 2026, cash and cash equivalents were £3.2 million (actual) and £6.8 million (pro forma).

• Total equity stood at £9.6 million (actual) and £13.2 million (pro forma), reflecting recent offerings and warrant exercises.

• Recent financings include a registered direct offering ($0.8M), private placement ($1.0M), and warrant inducements ($1.7M and $2.3M gross proceeds).

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by the selling shareholder; proceeds will only be received upon cash exercise of Series P Warrants.

• Funds are intended to support ongoing clinical development and business expansion.